DARIOHEALTH CORP Reports Second Quarter FY2023 Earnings Results on August 10
August 26, 2023
🌥️Earnings Overview
DARIOHEALTH ($NASDAQ:DRIO): On August 10 2023, DarioHealth Corp. reported their second quarter FY2023 earnings, ending June 30 2023. Total revenue decreased by 0.5% from the same period the previous year, amounting to USD 6.2 million. Net income was USD -16.6 million, a slight improvement from the year prior’s figure of -18.0 million.
Share Price
At the start of the day, DARIOHEALTH CORP stock opened at a price of $3.4 per share. By the end of the day, the stock closed at a price of $3.2, signifying a decrease of 8.4% from the last closing price of $3.4. This is the sixth consecutive quarter in which DARIOHEALTH CORP has reported a decrease in stock prices. It is yet to be seen what effect this will have on DARIOHEALTH CORP’s long-term outlook. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Dariohealth Corp. More…
| Total Revenues | Net Income | Net Margin |
| 26.63 | -58.47 | -201.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Dariohealth Corp. More…
| Operations | Investing | Financing |
| -33.03 | -0.42 | 18.31 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Dariohealth Corp. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 117.16 | 38.76 | 2.93 |
Key Ratios Snapshot
Some of the financial key ratios for Dariohealth Corp are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 55.2% | – | -200.9% |
| FCF Margin | ROE | ROA |
| -126.2% | -44.5% | -28.5% |
Analysis
GoodWhale has conducted an analysis of DARIOHEALTH CORP‘s fundamentals and our Star Chart shows that the company has a low health score of 2/10, considering its cashflows and debt, and is less likely to safely ride out any crisis without the risk of bankruptcy. Additionally, DARIOHEALTH CORP is strong in asset and growth but weak in dividend and profitability, leading us to classify it as a ‘cheetah’, a company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. This type of company may be of interest to investors who are looking for rapid growth and don’t mind taking on higher risks. Investors who prefer a steady return with lower risk may want to look elsewhere. More…
Peers
The company’s products are used by healthcare professionals to manage chronic conditions, such as diabetes, and by patients to improve their health and wellbeing. The company’s competitors include GBS Inc, Biocept Inc, and Abingdon Health PLC.
– GBS Inc ($NASDAQ:GBS)
Biocerpt Inc is a molecular diagnostics company that develops and commercializes proprietary circulating tumor cell (CTC) and circulating nucleic acid (CNA) tests. The company’s tests are designed to provide clinicians with personalized information to guide cancer therapy decisions. The company’s technology platforms include the Biocept CTC Platform, which is designed to capture, enumerate and analyze CTCs in a patient’s blood; and the Biocept CNA Platform, which is designed to capture, enumerate and analyze CNA from cells in a patient’s blood. The company’s tests are used for a variety of cancer types, including breast, non-small cell lung, small cell lung, gastric, colorectal, head and neck, and melanoma.
– Biocept Inc ($NASDAQ:BIOC)
Abingdon Health PLC is a UK-based medical technology company that develops, manufactures and markets rapid diagnostic tests. The company has a market capitalization of 8.82 million as of 2022 and a return on equity of -30.54%. Abingdon Health’s products are used in a variety of settings, including hospitals, clinics, physician offices, and laboratories. The company’s products are designed to provide quick and accurate results for a variety of medical conditions.
Summary
DARIOHEALTH CORP reported a decrease in total revenue of 0.5% and a net income of -16.6 million for their second quarter of FY2023 ending June 30 2023. This is a decrease from the prior year’s figure of -18.0 million, leading to a decrease in stock price on the same day. For investors, this could be a sign to be cautious when considering investing in DARIOHEALTH CORP, as the company has seen a decline in earnings and revenue in comparison to the prior year. However, a closer look into the company’s financials could help shareholders decide if DARIOHEALTH CORP is a wise investment choice.
Related Posts
Recent Posts
